TY - JOUR
T1 - Scale for the assessment and rating of ataxia
T2 - Development of a new clinical scale
AU - Schmitz-Hübsch, T.
AU - Du Montcel, S. Tezenas
AU - Baliko, L.
AU - Berciano, J.
AU - Boesch, S.
AU - Depondt, C.
AU - Giunti, P.
AU - Globas, C.
AU - Infante, J.
AU - Kang, J. S.
AU - Kremer, B.
AU - Mariotti, C.
AU - Melegh, B.
AU - Pandolfo, M.
AU - Rakowicz, M.
AU - Ribai, P.
AU - Rola, R.
AU - Schöls, L.
AU - Szymanski, S.
AU - Van De Warrenburg, B. P.
AU - Dürr, A.
AU - Klockgether, T.
PY - 2006/6
Y1 - 2006/6
N2 - OBJECTIVE: To develop a reliable and valid clinical scale measuring the severity of ataxia. METHODS: The authors devised the Scale for the Assessment and Rating of Ataxia (SARA) and tested it in two trials of 167 and 119 patients with spinocerebellar ataxia. RESULTS: The mean time to administer SARA in patients was 14.2 ± 7.5 minutes (range 5 to 40). Interrater reliability was high, with an intraclass coefficient (ICC) of 0.98. Test-retest reliability was high with an ICC of 0.90. Internal consistency was high as indicated by Cronbach's α of 0.94. Factorial analysis revealed that the rating results were determined by a single factor. SARA ratings showed a linear relation to global assessments using a visual analogue scale, suggesting linearity of the scale (p <0.0001, r = 0.98). SARA score increased with the disease stage (p <0.001) and was closely correlated with the Barthel Index (r = -0.80, p <0.001) and part IV (functional assessment) of the Unified Huntington's Disease Rating Scale (UHDRS-IV) (r = -0.89, p <0.0001), whereas it had only a weak correlation with disease duration (r = 0.34, p <0.0002) CONCLUSIONS: The Scale for the Assessment and Rating of Ataxia is a reliable and valid measure of ataxia, making it an appropriate primary outcome measure for clinical trials.
AB - OBJECTIVE: To develop a reliable and valid clinical scale measuring the severity of ataxia. METHODS: The authors devised the Scale for the Assessment and Rating of Ataxia (SARA) and tested it in two trials of 167 and 119 patients with spinocerebellar ataxia. RESULTS: The mean time to administer SARA in patients was 14.2 ± 7.5 minutes (range 5 to 40). Interrater reliability was high, with an intraclass coefficient (ICC) of 0.98. Test-retest reliability was high with an ICC of 0.90. Internal consistency was high as indicated by Cronbach's α of 0.94. Factorial analysis revealed that the rating results were determined by a single factor. SARA ratings showed a linear relation to global assessments using a visual analogue scale, suggesting linearity of the scale (p <0.0001, r = 0.98). SARA score increased with the disease stage (p <0.001) and was closely correlated with the Barthel Index (r = -0.80, p <0.001) and part IV (functional assessment) of the Unified Huntington's Disease Rating Scale (UHDRS-IV) (r = -0.89, p <0.0001), whereas it had only a weak correlation with disease duration (r = 0.34, p <0.0002) CONCLUSIONS: The Scale for the Assessment and Rating of Ataxia is a reliable and valid measure of ataxia, making it an appropriate primary outcome measure for clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=33745677486&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745677486&partnerID=8YFLogxK
U2 - 10.1212/01.wnl.0000219042.60538.92
DO - 10.1212/01.wnl.0000219042.60538.92
M3 - Article
C2 - 16769946
AN - SCOPUS:33745677486
VL - 66
SP - 1717
EP - 1720
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 11
ER -